USA
FDA Final Guidance on Technical Specifications for Clinical Data
The U.S. Food and Drug Administration (FDA) released two final guidance documents intended to support pharmaceutical companies in submitting standardized clinical data. These guidances provide technical specifications for submitting general Clinical Outcome Assessment (COA) data and Patient-Reported Outcome (PRO) data collected from oncology clinical studies. The objective is to improve the consistency and quality of clinical data submissions to the FDA.
Addressing the Impact of Medical Misinformation
The Reagan-Udall Foundation recently issued a report addressing the growing challenge of medical misinformation and its impact on public confidence in science and regulatory authorities. The report highlights strategies the FDA can adopt to improve public communication, strengthen transparency, and enhance understanding of the agency’s role and the products it regulates.
Importance of Comprehensive Responses to FDA Form 483
Although companies are not legally required to submit written responses to an FDA Form 483, regulatory experts strongly recommend doing so. According to Rebecca Asente, a compliance officer within the FDA’s Office of Regulatory Affairs, companies should provide well-structured and comprehensive responses that clearly describe corrective and preventive actions addressing the cited deficiencies. Properly organized responses help facilitate regulatory review and communication following inspections.
Draft Guidance on Remote Regulatory Assessments for Drug Facilities
The FDA has issued draft guidance describing its approach to voluntary Remote Regulatory Assessments (RRAs). These assessments allow the agency to evaluate manufacturing facilities remotely, either in place of or as a supplement to on-site inspections. RRAs may involve reviewing records, conducting virtual meetings, or assessing facility operations through remote tools.
Communications on Unapproved Use of Approved Products is Focus of Draft Guidance
The FDA has issued a draft guidance intended to strike a balance between health care providers’ interest in scientific information on unapproved uses of approved/cleared medical products and mitigating the FDA’s interest in prohibiting use of a product for an unapproved indication.
Draft Guidance on Communications Regarding Unapproved Uses of Approved Products
The FDA released draft guidance clarifying how companies may share scientific information related to unapproved uses of approved or cleared medical products. The guidance aims to balance the need for healthcare professionals to access scientific information with the agency’s responsibility to prevent promotion of products for unapproved indications.
Guidance on Risk-Benefit Assessment in Drug Regulation
The FDA issued final guidance explaining how risk-benefit considerations are evaluated during both premarket and postmarket regulatory decisions related to New Drug Applications (NDAs) and Biologics License Applications (BLAs). The document provides insight into how the agency assesses safety and effectiveness when making regulatory determinations.
Clinical Trial Development for Diabetic Foot Infection Drugs
A new draft guidance outlines recommendations for the development of drugs intended to treat diabetic foot infections (DFI). The document provides advice on designing clinical trials, establishing development programs, and evaluating safety and effectiveness for these therapies.
Quality Considerations for Ophthalmic Drug Products
The FDA also released draft guidance addressing quality considerations for ophthalmic drug products. Topics covered include the assessment of impurities, evaluation of visible particulate matter, container closure system design, stability testing, and the evaluation of extractables and leachables. The guidance also discusses in vitro drug release and dissolution testing methods used for quality control.
FDA IT Modernization Strategy
The FDA’s IT modernization strategy for fiscal years 2024 through 2027 emphasizes improvements in data sharing, electronic submissions, and collaboration with industry stakeholders. The plan also highlights the responsible integration of artificial intelligence and machine learning technologies to support clinical research and regulatory review processes.
Updated MAPP for ANDA Assessment Practices
The FDA has updated its Manual of Policies and Procedures (MAPP) related to Abbreviated New Drug Application (ANDA) assessment practices. The revisions are intended to streamline the review process and reduce the number of review cycles required before approval.
EUROPE
Electronic Product Information (ePI)
HMA, the European Commission, and EMA published the first electronic product information for selected medicines, making SmPCs, labeling, and package leaflets more accessible through digital platforms.
CTIS Training Module 10
EMA updated Module 10 of the CTIS training program to help stakeholders better understand submission, management, and withdrawal of Clinical Trial Applications.
Type I Variation Submissions
EMA advised marketing authorization holders to submit Type IA and Type IAIN variations before the end of November 2023 to support processing before the year-end closure.
Japanese Medicines Radiation Monitoring
Following withdrawal of the applicable EU regulation, authorities discontinued routine monitoring of medicines from Japan for Fukushima-related radioactive contamination while continuing broader safety surveillance.
CTIS Transparency Rules
EMA introduced revised transparency rules for CTIS, simplifying public access to clinical trial information and removing the previous data publication deferral mechanism.
Ireland Human Product Fee Form
HPRA published an updated fee application form for human medicinal products, including revised templates, fee codes, and submission categories.
ASIA
Singapore
WHO Listed Authority
Singapore’s Health Sciences Authority was recognized by WHO as a WHO-Listed Authority for medicines regulation, reflecting a high level of regulatory maturity and oversight.
Pakistan
Storage and Destruction Guideline
DRAP issued draft guidance describing procedures for handling, documenting, storing, and destroying substandard, falsified, or recalled therapeutic products.
New eService
DRAP launched an online platform supporting regulatory submissions for pharmaceutical and biological product registration and marketing authorization as part of its digital transformation program.
China
PIC/S Membership
China’s National Medical Products Administration obtained applicant status for membership in PIC/S, supporting alignment of its pharmaceutical inspection system with international standards.
